我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

瑞舒伐他汀和替米沙坦对原发性高血压并发阵发性心房纤颤治疗的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第1期
页码:
54-56
栏目:
临床研究
出版日期:
2012-02-25

文章信息/Info

Title:
Effects of rosuvastatin and telmisartan on patients with essential hypertension with paroxysmal atrial fibrillation
作者:
党寅虎丁抗宁李永勤张 琳牛小麟
(西安交通大学医学院第二医院心内科,陕西 西安 710004)
Author(s):
DANG Yin-hu DING Kang-ning LI Yong-qin ZHANG Lin NIU Xiao-lin
(Department of Cardiology, Second Hospital, Xi’an Jiaotong University, Xi’an 710004, Shaanxi, China0
关键词:
高血压原发性心房纤颤瑞舒伐他汀替米沙坦 P波离散度
Keywords:
essential hypertension atrial fibrillation rosuvastatin telmisartan P-wave dispersion
分类号:
R544.1;R541.7
DOI:
-
文献标识码:
A
摘要:
目的:观察瑞舒伐他汀和替米沙坦对原发性高血压(EH)并发阵发性心房纤颤(AF)患者心电图P波时限和离散度及AF发生率的影响。方法: EH并发阵发性AF患者56例,随机分为2组:替米沙坦(80 mg/d)加瑞舒伐他汀(10 mg/d)组(联合用药组)和替米沙坦(80 mg/d)组。共观察6个月。分别于用药前后测定12导联体表心电图中P波的时限和P波离散度及AF发生率。结果: 用药后两组均可使EH并发阵发性EH患者心电图P波的时限和P波离散度减小,组间比较显示,联合用药组的作用优于单用替米沙坦组。结论: 瑞舒伐他汀合用替米沙坦对EH并发阵发性AF患者窦律的维持及预防AF发生的作用优于单用替米沙坦。
Abstract:
AIM:To study the effects of rosuvastatin and telmisartan on P-wave dispersion in eletrocardiography in patients with essential hypertension (EH). METHODS: Fifty-six patients were randomly divided into telmisartan (80 mg/day) plus rosuvastatin (10 mg/day) group and telmisartan (80 mg/day) group and were monitored for 6 months. P-wave duration and P-wave dispersion were detected before and after using the drugs. RESULTS: After using the drugs, P-wave duration and P-wave dispersion in both groups of patients with EH decreased (P<0.05). Compared with telmisartan alone, rosuvastatin plus telmisartan had more obvious effect on P-wave dispersion. CONCLUSION: Treatment with rosuvastatin and telmisartan has more effective value in preventing atrial fibrillation than using telmisartan only in patients with EH.

参考文献/References

[1]Crandall MA,Horne BD,Day JD,et al.Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently[J].Acing Clin Electrophysiol,2009,32(5):648-652.

[2]Nakashima H,Kumagai K,Urata H,et al.Angiotensin Ⅱ antagonist prevents electrical remodeling in atrial fibrillation[J].Circulation,2000,101(22):2612-2617.

[3]Madrid AH,Bueno MG,Rebollo JM,et al.Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: aprospective and randomized study[J].Circulation, 2002, 106(3): 331-336.

[4]李永勤,王敏,范艳梅,等.维尔亚和依那普利对原发性高血压患者心电图P波离散度的影响[J].心脏杂志,2009,1(1):76-78.

[5]Jones PH,Davidson MH,Stein EA,et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,sinvastatin,and pravastatin acrossdoses (STELLAR Trial)[J].Am J Cardial,2003,92(2):152-160.

[6]瑞舒伐他汀中国注册临床研究协作组,瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211.

[7]李秋荣,王 勤,曲 环,等. 舒伐他汀对血脂正常的2型糖尿病患者血清高敏C反应蛋白的作用[J].中华高血压杂志,2011,19(3):280-282.

[8]徐建欧,陈小芬,卢益中,等.舒伐他汀对不稳定型心绞痛患者高敏C反应蛋白的影响[J].南方医科大学学报,2010,30(5):1195-196.

备注/Memo

备注/Memo:
收稿日期:2011-07-21.作者简介:党寅虎:副主任医师 Email:drdangyinhu@hot.mail.com
更新日期/Last Update: 2012-02-14